Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma.

Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M.

Virchows Arch. 2011 Jul;459(1):73-80. doi: 10.1007/s00428-011-1092-z. Epub 2011 May 24.

PMID:
21607649
2.

S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.

Tsai JH, Huang WC, Kuo KT, Yuan RH, Chen YL, Jeng YM.

Histopathology. 2012 Dec;61(6):1106-16. doi: 10.1111/j.1365-2559.2012.04316.x. Epub 2012 Aug 8.

PMID:
22882148
3.

Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.

Aishima S, Kuroda Y, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, Tsuneyoshi M.

Am J Surg Pathol. 2007 Jul;31(7):1059-67.

PMID:
17592273
4.

Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.

Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A, Shirabe K, Maehara Y, Oda Y.

Am J Surg Pathol. 2011 Apr;35(4):590-8. doi: 10.1097/PAS.0b013e31820ffdf1.

PMID:
21412073
5.

Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.

Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, Ikeda H, Sasaki M, Nimura Y, Nakanuma Y.

Liver Int. 2007 Nov;27(9):1174-84.

PMID:
17919228
6.

Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.

Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst-Hensch N, Kristiansen G, Jochum W.

Hum Pathol. 2010 Nov;41(11):1558-65. doi: 10.1016/j.humpath.2009.12.016.

PMID:
20621328
9.

Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion.

Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S, Kondo Y, Miyazaki M.

Am J Surg Pathol. 2011 Apr;35(4):512-21. doi: 10.1097/PAS.0b013e3182103f36.

PMID:
21412069
10.

Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.

Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y.

Hum Pathol. 2008 Aug;39(8):1153-61. doi: 10.1016/j.humpath.2007.11.018. Epub 2008 May 20.

PMID:
18495210
12.

Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.

Fujikura K, Fukumoto T, Ajiki T, Otani K, Kanzawa M, Akita M, Kido M, Ku Y, Itoh T, Zen Y.

Histopathology. 2016 Dec;69(6):950-961. doi: 10.1111/his.13037. Epub 2016 Sep 23.

PMID:
27410028
13.

Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.

Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, Sato E.

Hepatology. 1999 Dec;30(6):1347-55.

PMID:
10573510
14.

Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.

Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M.

Mod Pathol. 2003 Oct;16(10):1019-27.

15.

Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C.

World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.

PMID:
19294467
16.

Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.

Aishima S, Kuroda Y, Nishihara Y, Taguchi K, Iguchi T, Taketomi A, Maehara Y, Tsuneyoshi M.

Hum Pathol. 2007 Dec;38(12):1819-25. Epub 2007 Sep 14.

PMID:
17854859
17.

The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.

Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Sugimachi K, Tsuneyoshi M.

Mod Pathol. 2002 Nov;15(11):1181-90.

18.

Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.

Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y.

Hepatology. 2000 Oct;32(4 Pt 1):761-9.

PMID:
11003620
19.

Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas.

Hashimoto N, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, Masaki T, Kinoshita H, Tominaga M, Ajiki T, Ku Y, Okabayashi T, Hanazaki K, Hiroi M, Izumi S, Mano S, Okada S, Karasawa Y, Maeba T, Suzuki Y.

Ann Surg Oncol. 2009 Feb;16(2):395-403. doi: 10.1245/s10434-008-0236-0. Epub 2008 Nov 26.

PMID:
19034576
20.

Biliary intraductal papillary mucinous neoplasia: three case reports.

Yaman B, Nart D, Yilmaz F, Coker A, Zeytunlu M, Kilic M.

Virchows Arch. 2009 May;454(5):589-94. doi: 10.1007/s00428-009-0767-1. Epub 2009 Apr 4.

PMID:
19347361

Supplemental Content

Support Center